![]() will be presented at ASH.ĭaiichi Sankyo will hold its annual R&D Day for investors, analysts and media on Monday, December 11 at 5:30 - 7:00 pm EST/Tuesday, December 12 at 7:30 - 9:00 am JST. Additional subgroup analyses of the QuANTUM-First phase 3 trial in patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML), which formed the basis of recent approvals of VANFLYTA ® (quizartinib) in the EU, Japan and U.S. Subgroup analyses of the TROPION-Lung05 phase 2 trial of datopotamab deruxtecan (Dato-DXd) in Asian patients with non-small cell lung cancer (NSCLC) with actionable genomic alterations and the DESTINY-Lung02 phase 2 trial of ENHERTU in Asian patients with HER2 mutant NSCLC will be presented at ESMO Asia. “These data reinforce the breadth and depth of our oncology pipeline and the important progress we are making in developing innovative medicines and exploring combination strategies for patients across a wide range of cancers, including breast, lung, gastric, acute myeloid leukemia and peripheral T-cell lymphoma.” “Our goal is to push the boundaries of science to change the way cancer is treated,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. Presentation highlights include the first presentation of results from three trials from Daiichi Sankyo’s DXd ADC and hematology portfolio, which include the DESTINY-Gastric06 phase 2 trial of ENHERTU ® (trastuzumab deruxtecan) in Chinese patients with previously treated HER2 positive locally advanced/metastatic gastric cancer or gastroesophageal junction adenocarcinoma at ESMO Asia, the DESTINY-Breast08 phase 1b trial of ENHERTU in combination with anastrozole or fulvestrant in patients with HER2 low metastatic breast cancer at SABCS and the VALENTINE-PTCL01 phase 2 trial of valemetostat in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) at ASH. Keep it on Shacknews for the latest updates.BASKING RIDGE, N.J.-( BUSINESS WIRE)-Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio in multiple types of solid and blood cancers at the 2023 ESMO Asia Congress (#ESMOAsia23), San Antonio Breast Cancer Symposium (#SABCS23) and American Society of Hematology (#ASH23) Annual Meeting prior to its annual R&D Day. We've been captivated by Solar Ash throughout the past year, so we'll be sure to offer more details on the game as they come in. Look for it to release on PC (as an Epic Games Store exclusive), PlayStation 5, and PlayStation 4. Solar Ash now has a release date of October 26. This is also Heart Machine's first jump into a 3D adventure, a far leap from the 2D pixels of Hyper Light Drifter. Heart Machine's Alex Preston previously stated that the game would be set in the same universe as Hyper Light Drifter, but noted that it would not be a direct sequel. ![]() Solar Ash was first revealed last summer as part of the PlayStation 5 livestream reveal and an accompanying PlayStation.Blog post. And, as was the case with the Summer Game Fest 2021 trailer, there are massive boss creatures, which will require players to make the most of their traversal abilities in order to scale and topple the massive beasts. Players can also take a closer look at the main character's traversal abilities, which includes double jumps and grappling lines. The latest Solar Ash trailer offers a more melancholic look into this bright and mysterious world, showing off new environments like deserts, cloudy skies, and dark castles. Now it's back again, popping up during Thursday's Annapurna Interactive Showcase. Anticipation only grew after it showed up again at the Summer Game Fest 2021 showcase. ![]() The colorful landscapes showed that Heart Machine was ready to aim higher for its second project, following the breakout indie hit Hyper Light Drifter. ![]() Solar Ash dazzled players when it was first revealed prior to the release of the PlayStation 5.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |